An all-oral giredestrant-everolimus regimen lengthened progression-free survival after CDK4/6 inhibitors; tomosynthesis screening missed its interval-cancer endpoint

The edition in brief

In evERA, a phase 3 open-label trial of 373 patients with ER-positive, HER2-negative advanced breast cancer progressing after a CDK4/6 inhibitor with endocrine therapy, giredestrant plus everolimus gave median progression-free survival of 8.8 vs 5.5 months overall (HR 0.56, 95% CI 0.44 to 0.71) and 10.0 vs 5.5 months in ESR1-mutated tumours (HR 0.38, 0.27 to 0.54) compared with standard endocrine therapy plus everolimus; adverse event rates were similar. TOSYMA-2 followed screen-negative women in Germany for 24 months: invasive interval cancer rates were 14.2 vs 18.6 per 10,000 with tomosynthesis plus synthesised mammography versus digital mammography (adjusted OR 0.76, 95% CI 0.55 to 1.06; P=0.11), so the primary endpoint was not significant, while the 12-month rate was lower (OR 0.71, 0.52 to 0.97). REVERCE II randomised only 22 patients with refractory RAS wild-type metastatic colorectal cancer before closing, and its overall survival difference (21.9 vs 13.3 months) was not significant. A regulatory entry notes an FDA supplement to tucatinib. A pearl on molecular testing at progression closes the edition.